company background image
JULPHAR logo

Gulf Pharmaceutical Industries P.S.C ADX:JULPHAR Stock Report

Last Price

د.إ1.38

Market Cap

د.إ1.6b

7D

2.2%

1Y

47.9%

Updated

16 May, 2025

Data

Company Financials +

Gulf Pharmaceutical Industries P.S.C.

ADX:JULPHAR Stock Report

Market Cap: د.إ1.6b

JULPHAR Stock Overview

Manufactures and sells medicines, drugs, and various other types of pharmaceutical, cosmetic, and medical compounds in United Arab Emirates, other GCC countries, and internationally. More details

JULPHAR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance3/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 6.91% per year

Became profitable this year

Risk Analysis

No risks detected for JULPHAR from our risk checks.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Gulf Pharmaceutical Industries P.S.C. Competitors

Jiangxi Synergy Pharmaceutical

SZSE:300636

CN¥3.1b

Henan Taloph Pharmaceutical StockLtd

SHSE:600222

CN¥3.0b

Zhejiang Shengda Bio-Pharm

SHSE:603079

CN¥2.7b

Zhejiang Haisen Pharmaceutical

SZSE:001367

CN¥3.1b

Price History & Performance

Summary of share price highs, lows and changes for Gulf Pharmaceutical Industries P.S.C
Historical stock prices
Current Share Priceد.إ1.38
52 Week Highد.إ1.78
52 Week Lowد.إ0.80
Beta-0.23
1 Month Change4.55%
3 Month Change-6.76%
1 Year Change47.91%
3 Year Change12.20%
5 Year Change6.92%
Change since IPO-6.25%

Recent News & Updates

Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Screens Well But There Might Be A Catch

Apr 28
Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Screens Well But There Might Be A Catch

Statutory Profit Doesn't Reflect How Good Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Earnings Are

Mar 25
Statutory Profit Doesn't Reflect How Good Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Earnings Are

Recent updates

Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Screens Well But There Might Be A Catch

Apr 28
Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Screens Well But There Might Be A Catch

Statutory Profit Doesn't Reflect How Good Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Earnings Are

Mar 25
Statutory Profit Doesn't Reflect How Good Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Earnings Are

Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified

Oct 16
Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Jan 15
Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Nov 04
Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Mar 26
Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

Feb 08
Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

Dec 14
Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

Shareholder Returns

JULPHARAE PharmaceuticalsAE Market
7D2.2%-1.1%0.5%
1Y47.9%1.5%9.4%

Return vs Industry: JULPHAR exceeded the AE Pharmaceuticals industry which returned 1.5% over the past year.

Return vs Market: JULPHAR exceeded the AE Market which returned 9.4% over the past year.

Price Volatility

Is JULPHAR's price volatile compared to industry and market?
JULPHAR volatility
JULPHAR Average Weekly Movement6.3%
Pharmaceuticals Industry Average Movement6.1%
Market Average Movement4.3%
10% most volatile stocks in AE Market7.7%
10% least volatile stocks in AE Market2.8%

Stable Share Price: JULPHAR has not had significant price volatility in the past 3 months compared to the AE market.

Volatility Over Time: JULPHAR's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1980n/aBasel Nimer Ziyadehwww.julphar.net

Gulf Pharmaceutical Industries P.S.C., together with its subsidiaries, manufactures and sells medicines, drugs, and various other types of pharmaceutical, cosmetic, and medical compounds in United Arab Emirates, other GCC countries, and internationally. It operates through Manufacturing, Planet, Investments, and Others segment. The company offers generic medicines for pain and inflammation, antiviral, respiratory, anti-infectives, immunosuppressants and selective immunosuppressants, cardio care, CNS and psychiatry, vitamins and supplements, wound care management, dermatology, endocrine, gynecology and women care, anemia, antibiotics, decongestants and other nasal preparations, hyperkalemia and hyperphosphatemia, urinary antispasmodics, erectile dysfunction, benign prostatic hyperplasia, and gastrointestinal tract.

Gulf Pharmaceutical Industries P.S.C. Fundamentals Summary

How do Gulf Pharmaceutical Industries P.S.C's earnings and revenue compare to its market cap?
JULPHAR fundamental statistics
Market capد.إ1.59b
Earnings (TTM)د.إ21.80m
Revenue (TTM)د.إ1.33b

73.1x

P/E Ratio

1.2x

P/S Ratio

Is JULPHAR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JULPHAR income statement (TTM)
Revenueد.إ1.33b
Cost of Revenueد.إ806.30m
Gross Profitد.إ528.60m
Other Expensesد.إ506.80m
Earningsد.إ21.80m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.019
Gross Margin39.60%
Net Profit Margin1.63%
Debt/Equity Ratio55.9%

How did JULPHAR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/16 18:30
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gulf Pharmaceutical Industries P.S.C. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rim Ben Salah GharbiAlphaMena
null RESEARCH DEPARTMENTPrime Research